MannKind and United Therapeutics Strengthen Partnership for New Therapy
Strengthening Collaborations in Pulmonary Hypertension
MannKind Corporation, a prominent player in inhaled therapeutic products, has announced an exciting expansion of its collaboration with United Therapeutics Corporation. This partnership marks a significant milestone, as United Therapeutics has chosen to exercise its option under their 2018 agreement to delve into the development of a second dry powder inhalation therapy.
Details of the Expanded Agreement
The original collaboration led to the FDA approval of Tyvaso DPI, a vital treatment for pulmonary hypertension, back in May 2022. That agreement provided United Therapeutics the opportunity to broaden the scope of their collaboration to include additional active ingredients. Now, under this new phase, MannKind will utilize its proprietary Technosphere platform to formulate an innovative investigational molecule. Meanwhile, United Therapeutics is set to handle the preclinical and clinical development processes necessary to bring this new therapy to market.
CEO's Perspective on the Partnership
Michael Castagna, the Chief Executive Officer of MannKind Corporation, expressed his enthusiasm about this partnership. He stated, "Building on the success of Tyvaso DPI, we are proud to deepen our collaboration with United Therapeutics to bring innovative patient-centric inhaled therapies to patients living with pulmonary hypertension." He further emphasized that this development underscores the robust nature of their alliance and highlights the adaptability of their dry powder formulations and inhalation devices in addressing critical respiratory conditions.
Financial Aspects of the Deal
As part of this collaborative venture, MannKind is set to receive an upfront payment amounting to $5 million. Additionally, they stand to gain up to $35 million through various development milestones, along with a commendable 10% royalty on net sales of any resultant products.
Immediate Steps Toward Development
Formulation and development of the new investigational molecule are scheduled to commence without delay. This proactive approach demonstrates both companies' commitment to innovation and improved patient care.
Focus on Innovative Therapeutics
MannKind Corporation has been at the forefront of developing innovative inhaled therapeutic solutions aimed at addressing significant unmet medical needs. The company focuses particularly on health conditions affecting the endocrine system and orphan lung diseases. Their mission revolves around leveraging their formulation capabilities and device engineering expertise to help alleviate the burdens posed by serious medical conditions like diabetes, nontuberculous mycobacterial lung disease, pulmonary fibrosis, and pulmonary hypertension.
Commitment to Patient Care
The dedication of MannKind’s team, fondly referred to as Mannitarians, is evident in their mission to empower individuals to take control of their health. They prioritize enhancing patients’ quality of life and enabling them to live more freely through effective therapeutic options.
Learn More About MannKind
To stay informed about MannKind’s activities and advancements, individuals can follow their journey through their official website and social media channels. The company is committed to communicating its innovations and developments to both the medical community and the public.
Frequently Asked Questions
What is the purpose of the MannKind and United Therapeutics collaboration?
The collaboration focuses on developing a second inhaled therapy for pulmonary hypertension using MannKind’s proprietary Technosphere platform.
What financial benefits does MannKind receive from this agreement?
MannKind receives an upfront payment of $5 million, with potential earnings up to $35 million through development milestones and a 10% royalty on net sales.
What prior product resulted from the original collaboration?
The original collaboration led to the FDA approval of Tyvaso DPI, a treatment for pulmonary hypertension.
What is MannKind’s mission?
MannKind's mission is to develop therapeutics that enable patients to manage their health better, especially for serious medical conditions.
How does MannKind plan to enhance its inhaled therapies?
With a focus on innovation, MannKind plans to improve inhaled therapies through advanced formulation techniques and device engineering.
About The Author
Contact Hannah Lewis privately here. Or send an email with ATTN: Hannah Lewis as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.